

## Multiple Sclerosis, Injectable Drugs

### Goal(s):

- Promote safe and effective use of injectable or infused disease-modifying drugs for multiple sclerosis.

### Length of Authorization:

- Up to 12 months

### Requires PA:

- Non-preferred injectable or infused multiple sclerosis drugs (both pharmacy or provider administered claims).
- Note: Natalizumab should be reviewed under separate Natalizumab PA criteria.
- Note: Requests for Arzerra™ (ofatumumab) should be reviewed under the Oncology PA.

### Covered Alternatives:

- Current PMPDP preferred drug list per OAR 410-121-0030 at [www.orpdl.org](http://www.orpdl.org)
- Searchable site for Oregon FFS Drug Class listed at [www.orpdl.org/drugs/](http://www.orpdl.org/drugs/)

Approval Criteria		
1. What diagnosis is being treated?	Record ICD10 code.	
2. Is the request for an FDA-approved form of multiple sclerosis (see Table 1)?	<b>Yes:</b> Go to #3.	<b>No:</b> Pass to RPH; Deny for medical appropriateness.
3. Is this a request for continuation of therapy?	<b>Yes:</b> Go to <b>Renewal Criteria</b>	<b>No:</b> Go to #4
4. Is the drug prescribed by or in consultation with a neurologist?	<b>Yes:</b> Go to # 5	<b>No:</b> Pass to RPh. Deny; medical appropriateness
5. Is the patient on concurrent treatment with a disease modifying drug (i.e., glatiramer, interferon, mitoxantrone, natalizumab, ofatumumab, ocrelizumab, or peginterferon) to treat MS?	<b>Yes:</b> Pass to RPh. Deny; medical appropriateness.	<b>No:</b> Go to #6
6. Is there documentation of recommended baseline testing to mitigate safety concerns (Table 2)?	<b>Yes:</b> Go to #7	<b>No:</b> Pass to RPh. Deny; medical appropriateness.
7. Is the request for a drug with potential risks during pregnancy (e.g., ofatumumab, mitoxantrone, or ublituximab)?	<b>Yes:</b> Go to #8	<b>No:</b> Approve for up to 1 year
8. Is the patient of childbearing potential?	<b>Yes:</b> Go to #9	<b>No:</b> Approve for up to 1 year

Approval Criteria		
9. Is the patient pregnant or actively trying to conceive?	<b>Yes:</b> Pass to RPh. Deny; medical appropriateness.	<b>No:</b> Go to #10
10. Is there documentation that the provider and patient have discussed the teratogenic risks of the drug if the patient were to become pregnant?	<b>Yes:</b> Approve for up to 1 year	<b>No:</b> Pass to RPh. Deny; medical appropriateness.

Renewal Criteria		
1. Has the patient's condition stabilized (i.e., reduced activity seen on magnetic resonance imaging (MRI), fewer relapses, and/or minimal or no disease progression) as assessed by the prescribing physician and physician attests to patient's improvement?	<b>Yes:</b> Approve for 12 months.  Document baseline assessment and physician attestation received.	<b>No:</b> Pass to RPh; Deny; medical appropriateness.

**Table 1. FDA-Approved Indications for Injectable MS Drugs**

Generic Name	Brand Name	FDA Indication			
		CIS	RRMS	SPMS	PPMS
Alemtuzumab	LEMTRADA		X	X	
Glatiramer acetate	GLATOPA, COPAXONE	X	X	X	
Interferon beta-1a	AVONEX, REBIF	X	X	X	
Interferon beta-1b	BETASERON, EXTAVIA	X	X	X	
Mitoxantrone	NOVANTRONE		X	X	
Ocrelizumab	OCREVUS	X	X	X	X
Ocrelizumab and hyaluronidase-ocsq	OCREVUS ZUNOVO	X	X	X	X
Ofatumumab	KESIMPTA	X	X	X	
Ublituximab	BRIUMVI	X	X	X	

Abbreviations: CIS = clinically isolated syndrome; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis

**Table 2. FDA-Recommended Baseline Safety Assessments**

	LFTs	CBC	Thyroid Function Tests	Hepatitis B Virus Screening	Other Screening
Alemtuzumab	X	X	X		VZV and TB Screening, SCr, UA, up to date with all vaccinations, completed screening for John Cunningham (JC) virus
Glatiramer acetate					
Interferon beta-1a	X	X	X		

Interferon beta-1b	X	X	X		
Mitoxantrone	X	X			ECG and LVEF, negative pregnancy test
Ocrelizumab				X	Serum immunoglobulins, up to date with all vaccinations, completed screening for John Cunningham (JC) virus
Ocrelizumab hyaluronidase-ocsq				X	Serum immunoglobulins, up to date with all vaccinations, completed screening for John Cunningham (JC) virus
Ofatumumab				X	Serum immunoglobulins, up to date with all vaccinations, negative pregnancy test, completed screening for John Cunningham (JC) virus
Ublituximab				X	Serum immunoglobulins, up to date with all vaccinations, negative pregnancy test prior to each infusion, completed screening for John Cunningham (JC) virus
Abbreviations: CBC = complete blood count; ECG = electrocardiogram; FDA = U.S. Food and Drug Administration; JCV = John Cunningham Virus; LFTs = liver function tests; LVEF= left ventricular ejection fraction; PML = progressive multifocal leukoencephalopathy; SCr = serum creatinine; TB = tuberculosis; UA = urinalysis; VZV = varicella zoster virus					

*P&T / DUR Action:* 10/25 (DM); 10/24 (DM); 10/22 (DM)  
*Implementation:* 1/1/26; 12/1/2024; 1/1/23